Success Story: Our Expert Helped an Indian Senior Data Scientist Secure NIW Approval Without Any RFE Issues
Client’s Testimonial:
"Working with the Chen Immigration team was honestly one of the best decisions I made during my NIW process. They truly understood my research and professional work and knew exactly how to present it in a way that showed its real impact. I always felt supported, informed, and confident that my case was in expert hands. Their attention to detail and strategic approach made the entire process smooth, and getting approval without any RFE was incredibly reassuring. I’m genuinely thankful for their guidance and would wholeheartedly recommend them to anyone pursuing an NIW petition.”
On June 18th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Data Scientist in the Field of Data Science (Approval Notice).
General Field: Data Science
Position at the Time of Case Filing: Senior Data Scientist
Country of Origin: India
State of Residence at the Time of Filing: New Jersey
Approval Notice Date: June 18th, 2025
Processing Time: 5 months, 3 days
Case Summary:
Drawing on our extensive experience and a proven track record of more than 32,000 approved cases, our team recently secured a National Interest Waiver approval for a data science researcher in the field of advanced pharmaceutical manufacturing. The petition was approved without a Request for Evidence, reflecting the strength and clarity of the evidence we strategically presented.
Background & Field of Expertise
The client holds a Ph.D. in chemical and biochemical engineering and has built recognized expertise in data science as it applies to the pharmaceutical sector. This work directly aligns with critical national priorities—reducing drug shortages, improving production sustainability, and supporting continued U.S. leadership in high-value pharmaceutical innovation.
Strong Evidence of Research Excellence
To demonstrate the client’s prominent standing in the field, we highlighted:
- 9 peer-reviewed journal articles (including 2 first-authored)
- 2 peer-reviewed conference papers (1 first-authored)
- 1 first-authored abstract
- A total of 210 citations to the client’s published body of work
- At least 25 completed peer reviews for respected scientific journals
- Major funding support from prestigious organizations such as the Korea Health Industry Development Institute and GlaxoSmithKline
Recommendation Letters from Field Experts
We also included compelling letters from independent and collaborative experts, providing strong validation of the client’s national importance.
These letters underscored that the client’s contributions are already improving manufacturing reliability and compliance—both critical to U.S. patient care and economic interests.
The Approval
The petition was approved cleanly and efficiently, showcasing the effectiveness of our proactive approach. We anticipated USCIS concerns from the outset and provided authoritative evidence that satisfied all NIW criteria without further inquiry.
This approval highlights how specialized contributions in data science applied to pharmaceutical manufacturing can easily meet the NIW standard when clearly linked to advancing U.S. healthcare capabilities and economic stability.
It was our honor to guide this exceptional researcher to a successful outcome, and we look forward to seeing the impact of continued work that strengthens the quality, safety, and accessibility of essential medicines in the United States.